Palvella Appoints Kent Taylor to Drive U.S. Sales for 30,000-Patient QTORIN™ Market
Palvella Therapeutics appointed Kent Taylor, ex-Arcutis and Incyte SVP of Sales, to lead U.S. sales ahead of potential QTORIN™ rapamycin launch for microcystic lymphatic malformations. Taylor’s 25-year commercial experience includes driving the launches of ZORYVE® and OPZELURA® and building sales teams of over 170 representatives.
1. Strategic Appointment
Palvella Therapeutics named Kent Taylor as Senior Vice President of Sales to build and lead its U.S. commercial organization in preparation for the potential launch of QTORIN™ rapamycin for microcystic lymphatic malformations. This role underscores the company’s focus on establishing a dedicated sales infrastructure ahead of anticipated regulatory approval.
2. Proven Commercial Track Record
Taylor brings over 25 years of pharmaceutical commercial leadership, having most recently served as SVP of Sales at Arcutis Biotherapeutics where he managed U.S. efforts for ZORYVE®. He also led the launch of OPZELURA® cream at Incyte, recruiting and managing a team of more than 170 sales professionals across dermatology indications.
3. Preparations for QTORIN™ Launch
QTORIN™ rapamycin targets microcystic lymphatic malformations, a rare genetic disorder affecting an estimated 30,000 diagnosed patients in the U.S. With no FDA-approved therapies currently available, Palvella is positioning its sales force under Taylor’s leadership to capture this high unmet-need market upon approval.